In another study published by Wang et al. (54), authors assessed the sensitivity of the PD-1 treatment (nivolumab) on CMT167-induced cancer (bone cancer associated), and PD-L1 was expressed at baseline (exosome serum). Here, PDCD1 is linked to cancer.